Objective  To conduct data mining of asthma-inducing medications in underage populations based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, so as to provide reference for the clinical application of related medications.

Methods  Adverse drug event (ADE) reports from the first quarter of 2013 to the fourth quarter of 2022 in the FAERS database were collected and screened for reports of asthma adverse events in the this population (under 18 years old), which were categorized into infants, toddlers, children, and adolescents according to different age groups, and were subjected to medication signal mining by using the reporting odds ratio method, the composite standardized method, and the information component method.

Results  A total of 1 915 reports were obtained after screening, involving 1 042 (54.41%) males and 831 (43.39%) females; the highest percentage of the reporting population was between 12 and under 18 years old, with a total of 762 (39.79%); 60.78% of the reports were reported by health professionals; and the results of the clinical referrals showed that serious adverse events occurred in 85.90% of the cases. 306 suspected drugs were screened, 52 drugs were determined to be valid signals, and 1 044 adverse events were reported, of which 16 drug inserts did not mention the risk of asthma, in order of elosulfatase alpha, canakinumab, tobramycin, vancomycin, ceftriaxone, cetirizine, phenylephrine, imiglucerase, cefuroxime, betamethasone, atropine, tadalafil, riscovastatin, cyclophosphamide, octreotide, and omeprazole.

Conclusion  The FAERS database was mined for adverse drug event signals and evaluated using the proportional disequilibrium method to identify 16 medicines that may trigger pharmacogenetic asthma and are not documented in the specification, which can be used to provide a good early warning for the clinic. At the same time, focusing on special populations, strengthening the assessment of lung function before medication and monitoring during and after medication, timely interventions were taken to reduce the harm of drug-derived adverse reactions and ensure the safe use of medication.

1.Wang Q, Zhang W, Liu L, et al. Effects of physical therapy on lung function in children with asthma: study  protocol for a systematic review and meta-analysis[J]. Medicine (Baltimore), 2019, 98(15): e15226. DOI: 10.1097/MD.0000000000015226.

2.Macedo TM, Freitas DA, Chaves GS, et al. Breathing exercises for children with asthma[J]. Cochrane Database Syst Rev, 2016, 4(4): CD011017. DOI: 10.1002/14651858.CD011017.pub2.

3.张静, 殷勇. 儿童哮喘家庭教育现状[J]. 中国实用儿科杂志, 2020, 35(3): 237-241. [Zhang J, Yin Y. Current status of family education in childhood asthma [J]. Chinese Journal of Practical Pediatrics, 2020, 35 (3): 237-241.] DOI: 10.19538/j.ek2020030617.

4.Zahran HS, Bailey CM, Damon S , et al. Vital signs: asthma in children-United States, 2001-2016[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(5): 149-155. DOI: 10.15585/mmwr.mm6705e1.

5.任洁. 6岁以下儿童哮喘诊断标准验证的多中心研究[J]. 中国实用儿科杂志, 2021, 36(12): 947-950. [Ren J. Multicenter study on validation of diagnostic criteria for asthma in children under 6 years[J]. Chinese Journal of Practical Pediatrics, 2021, 36(12): 947-950.] DOI: 10. 19538/j.ek2021120614.

6.刘树俊, 王婷婷, 曹世钰, 等. 中国儿童哮喘危险因素的Meta分析[J]. 中国当代儿科杂志, 2018, 20(3): 218-223. [Liu SJ, Wang TT, Cao SY, et al. Meta-analysis of risk factors for asthma in Chinese children [J]. Chinese Journal of Contemporary Pediatrics, 2018, 20(3): 218-223.] DOI: 10.7499/j.issn.1008-8830.2018.03.011.

7.Sun W, Pan L, Zhang W. Risk factors for readmission of children hospitalized with acute asthma attacks in South China[J]. J Asthma, 2021, 58(4): 438-447. DOI: 10.1080/02770903.2019.1705334.

8.肖惠迪, 书文, 李梦龙, 等. 中国2011—2018年儿童哮喘患病率Meta分析[J]. 中国学校卫生, 2020, 41(8): 1208-1211. [Xiao HD, Shu W, Li ML, et al. Prevalence of childhood asthma in China from 2011 to 2018: a Meta-analysis[J]. Chinese Journal of School Health, 2020, 41(8): 1208-1211.] DOI: 10.16835/j.cnki.1000- 9817.2020.08.023.

9.冷芳. 重视药源性哮喘促进合理用药[J]. 中国医药指南, 2014, 12(30): 381-382. [Leng F. Emphasis on drug-derived asthma to promote rational drug use[J]. Guide of China Medicine, 2014,12 (30): 381-382.] DOI: 10.15912/j.cnki.gocm.2014.30.288.

10.闫芳, 卢秀芹. 抗菌药物所致药源性哮喘[J]. 临沂医学专科学校学报, 2003, 25(5): 393-394. [Yan F, Lu XQ. Drug-borne asthma induced by antimicrobial agents[J]. Journal of Shandong Medical College, 2003, 25(5): 393-394.] DOI: 10.3969/j.issn.1674-0947.2003.05.045.

11.韩咏霞. 警惕6类药物诱发药源性哮喘[J]. 解放军健康, 2014(3): 29. [Han YX. Be alert to class 6 drugs-induced drug-borne asthma[J]. PLA Health, 2014(3): 29.] DOI: CNKI:SUN:YWYR.0.2013-10-023.

12.丁满拴, 马仙英, 武保福, 等. 药源性哮喘浅析[J]. 药物流行病学杂志, 2002, 11(2): 64-66. [Ding MS, Ma XY, Wu BF, et al. Brief analysis of drug-induced asthma [J].Chinese Journal of Pharmacoepidemiology, 2002, 11(2): 64-66.] DOI: 10.3969/j.issn.1005-0698.2002.02.005.

13.de Benedictis FM, Attanasi M. Asthma in childhood[J]. Eur Respir Rev, 2016, 25(139): 41-47. DOI: 10.1183/ 16000617.0082-2015.

14.何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920. [He X, Ma JL, Yang GP. Analysis of adverse events in HER2 conjugated antibodies via FAERS[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 915-920.] DOI: 10.19803/j.1672-8629.20220658.

15.吴斌, 吴逢波, 罗敏, 等. MedEx在FAERS药品名称标准化中的应用[J]. 中国医院药学杂志, 2019, 39(19): 1989-1992. [Wu B, Wu FB, Luo M, et al. Application of MedEx in FAERS drug names standardization[J]. Chinese Journal of Hospital Pharmacy, 2019, 39(19): 1989-1992.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.19.16.

16.陈哲, 林茂, 曾力楠, 等. 水合氯醛口服溶液用于儿童镇静催眠安全性的系统评价[J]. 中国药房, 2020, 31(9): 1124-1131. [Chen Z, Lin M, Zeng LN, et al. Chloral hydrate oral solution for a systematic evaluation of the safety of sedative hypnosis in children[J]. China Pharmacy, 2020, 31(9): 1124-1131.] DOI: 10.6039/j.issn.1001- 0408.2020.09.19.

17.Akol A, Makumbi F, Babirye JN, et al. Does mhGAP training of primary health care providers improve the identification of child- and adolescent mental, neurological or substance use disorders? Results from a randomized controlled trial in Uganda[J]. Glob Ment Health (Camb), 2018, 5: e29. DOI: 10.1017/gmh.2018.18.

18.叶小飞. 基于自发呈报系统与循证医学的药品不良反应信号挖掘[D]. 上海: 第二军医大学, 2011. DOI: 10.7666/d.d151242.

19.Ang PS, Chen Z, Chan CL, et al. Data mining spontaneous adverse drug event reports for safety signals in Singapore-a comparison of three different disproportionality measures[J]. Expert Opin Drug Saf, 2016, 15(5): 583-590. DOI: 10.1517/14740338.2016.1167184.

20.杨瑞红, 何权瀛. 药源性哮喘[J]. 药物不良反应杂志, 2006, 8(1): 45-49. [Yang RH, He QY. Drug-derived asthma[J]. Adverse Drug Reactions Journal, 2006, 8(1): 45-49.] DOI: CNKI:SUN:YWBL.0.2006-01-018.

21.韦永先, 吕翠兰. 口服阿托品引起支气管哮喘1例报告[J]. 陕西新医药, 1985(10): 57-58. [Wei YX, Lu CL. Oral atropine caused bronchial asthma in a case report[J]. Shaanxi Medical Journal, 1985(10): 57-58.] http://www.cnki.com.cn/Article/CJFDTotal-SXYZ198510027.htm.

22.沈美意. 妥布霉素致过敏性哮喘1例[J]. 中国新药杂志, 2004, 13(2): 160-160. [Shen MY. A case report of allergic asthma caused by tobramycin[J]. China Journal of New Drugs, 2004, 13(2): 160-160.] DOI: 10.3321/j.issn:1003-3734.2004.02.027.

23.陈靖, 梁晓慧, 聂红卫. 头孢呋辛钠引发支气管哮喘1例[J]. 临床军医杂志, 2008, 36(5): 723. [Chen J, Liang XH, Nie HW. Cefuroxime sodium caused bronchial asthma[J]. Clinical Journal of Medical Officers, 2008, 36(5): 723.] DOI: CNKI:SUN:JYGZ.0.2008-05-034.

24.彭秋燕, 陈丽芳, 黄淑萍. 头孢曲松钠致73例儿童不良反应分析[J]. 天津药学, 2016, 28(3): 20-22. [Peng QY, Chen LF, Huang SP. Analysis of adverse reactions in 73 children caused by ceftriaxone sodium[J]. Tianjin Pharmacy, 2016, 28 (3): 20-22.] DOI: 10.3969/j.issn. 1006-5687.2016.03.008.

25.畅凤霞,王健.头孢曲松钠致支气管哮喘加重一例 [J]. 中国呼吸与危重监护杂志, 2005, 4(2): 83. [Chang FX, Wang J. A case of bronchial asthma aggravated by ceftriaxone sodium[J]. Chinese Journal of Respiratory and Critical Care Medicine, 2005, 4(2): 83.] DOI: 10.3969/j.issn.1671-6205.2005.02.021.

26.Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine[J]. Clin Sci (Lond), 2017, 131(14): 1723-1735. DOI: 10.1042/CS20160253.

27.李仕荣, 仇军. 常见引起支气管哮喘的药物[J]. 中国伤残医学, 2008, 16(2): 74-75. [Li SR, Qiu J. Drugs that commonly cause bronchial asthma [J]. Chinese Journal of Trauma and Disability Medicine, 2008, 16(2): 74-75.] DOI: 10.3969/j.issn.1673-6567.2008.02.075.

28.孙淑娟. 药源性支气管哮喘[J]. 中国临床医生, 2009, 37(2): 55-58. [Sun SJ. Drug-induced bronchial asthma[J]. Chinese Journal for Clinicians, 2009, 37 (2): 55-58.] DOI: 10.3969/j.issn.1008-1089.2009.02.023.

29.Abdelaziz RR, Elkashef WF, Said E. Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis[J]. Int Immunopharmacol, 2016, 40: 530-541. DOI: 10.1016/j.intimp.2016.10.007.

30.李剑, 佟金平, 苗姝. 瑞舒伐他汀对支气管哮喘患者气道炎症、肺功能及病情控制的影响[J]. 中国医学创新, 2021, 18(2): 60-63. [Li J, Tong JP, Miao S. Impact of rosuvastatin on airway inflammation, pulmonary function and disease control of patients with bronchial asthma[J]. Medical Innovation of China, 2021,18 (2): 60-63.] DOI: 10.3969/j.issn.1674-4985.2021.02.015.

31.李雅杰. 大剂量环磷酰胺冲击治疗重症哮喘病人的护理[J]. 齐齐哈尔医学院学报, 2005, 26(1): 81. [Li YJ. Care of high-dose cyclophosphamide shock therapy for patients with severe asthma[J]. Journal of Qiqihar Medical University, 2005, 26(1): 81.] DOI: 10.3969/j.issn.1002-1256.2005.01.065.

32.Tack J, Pandolfino JE. Pathophysiology of gastroesophageal reflux disease[J]. gastroenterology, 2018, 154(2): 277-288. DOI: 10.1053/j.gastro.2017.09.047.

33.Yu RJ, Krantz MS, Phillips EJ, et al. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)[J]. J Allergy Clin Immunol Pract, 2021, 9(2): 819-829. e2. DOI: 10.1016/j.jaip.2020.09.021.

34.Kamitaki BK, Minacapelli CD, Zhang P, et al. Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS) [J]. Epilepsy Behav, 2021, 117: 107832. DOI: 10.1016/j.yebeh.2021.107832.